Navigation Links
New drug active against most aggressive type of lung cancer cells
Date:7/10/2014

Manchester scientists have shown that a new drug could prove useful in treating small cell lung cancer - the most aggressive form of lung cancer.

Scientists from the Cancer Research UK Manchester Institute, based at The University of Manchester and part of the Manchester Cancer Research Centre, teamed up with experts at AstraZeneca, as part of a collaboration agreed in 2010, to test a drug known as AZD3965 - on small cell lung cancer cells.

The research, published in the journal Clinical Cancer Research, also helps identify which patients are most likely to respond to the treatment.

One treatment approach currently being investigated by cancer scientists is finding drugs that exploit the change in energy production in tumours. In cancer cells there is a switch to using glycolysis, a process that requires less oxygen and produces lactate as a by-product. Certain molecules monocarboxylate transporters (MCTs) are involved in the movement of lactate out of cells and drugs that target MCTs have been shown to stop tumour growth.

The Manchester researchers tested a new drug that targets one of these molecules, MCT1, in lung cancer cells and in mouse models.

Professor Caroline Dive, who led the research, said: "Small cell lung cancer has a dismal prognosis and we have seen little improvement in treatment for many years. More targeted therapies are needed to help those patients whose tumours become resistant to chemotherapy. This new drug AZD3965 is currently in clinical trials, but it has not yet been tested in small cell lung cancer."

The team investigated the sensitivity of small cell lung cancer cells to AZD3965 and showed that in those cells lacking an alternate lactate transporter, MCT4, the drug had an effect. They found that the drug increased the level of lactate in cells and, more importantly, reduced tumour growth.

They then looked at tumour samples taken from lung cancer patients and found that high levels of MCT1 were linked to worse patient prognosis.

Professor Dive added: "We propose that this drug will be most useful in this subset of patients who have elevated MCT1 levels and need more effective treatments.

"Our laboratory results are promising and certainly provide encouragement to test this treatment clinically in patients with small cell lung cancer."

Susan Galbraith, head of the oncology innovative medicines unit at AstraZeneca, said: "Lung cancer is still the leading cancer killer, and we are working on a number of potential treatment options that could provide patients with a better chance of beating the disease. Targeting tumour cell metabolism represents a novel and exciting approach, and we are delighted to be working with The University of Manchester and Cancer Research UK to investigate the utility of AZD 3965 as a potential novel cancer treatment."


'/>"/>

Contact: Alison Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester
Source:Eurekalert

Related medicine news :

1. Most prostate cancer specialists dont recommend active surveillance for low-risk patients
2. Keeping active pays off even in your 70s and 80s
3. A new Kabuto-like nickel catalyst forms bioactive frameworks from phenol derivatives
4. Screen of existing drugs finds compounds active against MERS coronavirus
5. Faster dental treatment with new photoactive molecule
6. Resin infiltration effects in a caries-active environment -- 2 year results
7. Beaumont holds first international congress on underactive bladder
8. Beauty & bacteria: Slim, attractive men have less nasal bacteria than heavy men
9. Attractive professional cyclists are faster
10. PhUSE Working Group Active in Developing Standard Analysis Scripts
11. Rehabilitation Robots, Active Prostheses, and Exoskeletons: Market Shares, Strategies, and Forecasts, Worldwide, 2014 to 2020 New Report Available at ReportsnReports.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate ... in Latin America . ... ... ... ...
Breaking Medicine Technology: